InvestorsHub Logo
Followers 4
Posts 372
Boards Moderated 0
Alias Born 08/13/2019

Re: oneragman post# 212758

Thursday, 09/05/2019 11:25:38 AM

Thursday, September 05, 2019 11:25:38 AM

Post# of 425915

Atom,

"4.8% of people who experience a primary efficacy end point"

That statement cannot be correct...think about it.



My other post got deleted, but I wanted to make sure you knew you were right.

That should have read, "4.8% of people on Vascepa who did not experience a primary efficacy end point" (i.e. deaths prevented by treatment)

Sorry for the confusion!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News